Review of CLEAR and CheckMate-9ER: Four-Year and 55 Month Follow-Up Data
Matthew Campbell, MD, MS, analyzes the crucial efficacy and safety results from the CLEAR trial's 4-year final analysis, incorporating insights on how these findings influence clinical decision-making for treatment-naïve patients with advanced renal cell carcinoma.
- Dr Campbell: Please briefly review key efficacy and safety data from the CLEAR trial 4-year final analysis (Motzer et al. J Clin Oncol. 2024),
- What are the clinical implications of these data for treatment-naïve patients with advanced RCC?
- In responders, how important is the durability of the response (OS) based on the original response (CR, PR with ≥75% reduction, PR with ≥30% to <75% reduction) for both the intermediate/poor and favorable-risk group?
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
